Here are the top 5 inflammation pieces of 2025; stay up-to-date with all the inflammation content from The American Journal ...

Our top RSV content of 2025 included how nirsevimab and clesrovimab changed RSV prevention among younger patients, as well as ...

Although frontline maintenance treatment with fuzuloparib monotherapy produced a progression-free survival (PFS) benefit in patients with newly diagnosed advanced ovarian cancer, the addition of ...

Our content coverage from the Southeastern Educational Congress of Optometry (SECO) 2025 provided information on a mix of ...

Discover the latest breakthroughs in myasthenia gravis treatment, including rozanolixizumab and nipocalimab, and insights on ...

Here are the top 5 ovarian cancer articles of 2025; stay up-to-date with all the ovarian cancer content from The American ...

The top Managed Care Cast episodes explored wellness visits, weight loss drug access, neurospine care, public health policy, ...

The 2025 pharmaceutical pipeline is expanding with generics, biosimilars, and new therapies, despite delays from patent ...

Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...

The top 5 infectious disease stories on AJMC.com this year covered both outbreaks and government-related developments. Bird ...

The GLOVe regimen, combining glofitamab, lenalidomide, and venetoclax, shows rapid and deep responses in high-risk MCL ...

Remote therapeutic monitoring (RTM) of patients with blood cancers cut hospitalizations from infections by 52% over 2 years ...